Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

Merck & TissueGene’s Drugs to Change Osteoarthritis Market

By GlobalData | February 25, 2016

The osteoarthritis space will experience seismic changes over the next decade, as disease-modifying drugs are expected to launch for the first time into a market currently dominated by a host of generic pain-relieving treatments, according to an analyst with research and consulting firm GlobalData.

The late-stage development pipeline currently comprises two such drugs, namely TissueGene’s Invossa and Merck Serono’s sprifermin, which are expected to launch in the US in 2020 and 2021, respectively. Both drugs have shown evidence of slowing disease progression, and Invossa was also found to reduce osteoarthritis pain in trials.

As Lu Chen, Ph.D., GlobalData’s Analyst covering Immunology, explains: “Without disease-modifying modalities that slow or reverse the disease progression, many osteoarthritis patients eventually require joint replacement surgeries and may become disabled. Thus, the need for disease-modifying drugs for osteoarthritis is immense, particularly considering that the condition is a leading cause of disability in developed countries.

“Despite this need, osteoarthritis can appear to be static for a long time and mild cases are largely managed by inexpensive generic drugs. In this way, therapies such as Invossa and sprifermin may experience slow adoption and be limited to use in more severe cases initially.”

Following sluggish initial uptake, assuming that disease-modifying drugs overcome reimbursement barriers and fully establish their cost-effectiveness, GlobalData anticipates broader use of these therapeutics in the long term.

Chen continues: “Both Invossa and sprifermin hold the potential to drastically change the osteoarthritis disease treatment paradigm and market.

“Sprifermin is likely to cost less than Invossa, and therefore experience better uptake initially. However, as Invossa is more expensive, and has the added benefit of lowering pain as well as slowing joint deterioration, it will likely achieve US sales of over $560 million in 2024, compared with around $310 million for sprifermin.”

Follow us on Twitter and Facebook for updates on the latest pharmaceutical and biopharmaceutical manufacturing news!


Filed Under: Drug Discovery

 

Related Articles Read More >

Novartis in the Pharma 50
Novartis to cut up to 8,000 positions
Gilead Sciences in the Drug Discovery & Development Pharma 50
Gilead resubmits application to FDA for twice-yearly HIV drug lenacapavir
George Floyd mural
How the pandemic and George Floyd made clinical trial diversity a priority
Portrait photo of Pfizer EVP and Medtronic board member Lidia Fonseca
Medtronic appoints Pfizer EVP as independent board director

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MASSDEVICE
  • DEVICETALKS
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • MEDTECH 100
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50